Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Exploratory study in adult males with metastatic prostate cancer intended to characterize the
pharmacokinetics and biodistribution of PSMA-Targeted [In-111]-Labeled Trillium Compounds
with and without the cytoprotective agent PTI-122. Up to 36 eligible subjects will be
enrolled. Additional subjects may be enrolled if there is insufficient data for evaluation,
for example if the original study subjects do not complete required imaging studies for
reasons unrelated to adverse events.
Up to four PSMA-Targeted [In-111]-Labeled Trillium Compounds will be evaluated. Each compound
will be evaluated first without the cytoprotective agent, PTI-122, then the [In-111]-labeled
Trillium Compound may be co-administered with PTI-122.